Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus MICORT HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus MICORT HC.
CORTAN vs MICORT-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release, thereby exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Topical: Apply a thin film to affected area 2-4 times daily. Rectal: Insert one suppository (25 mg) rectally twice daily (morning and evening) for 2-3 weeks, then taper as needed.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal elimination half-life is 1.5-2.5 hours; clinical duration of action is longer due to genomic effects lasting 8-12 hours.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Renal (approximately 70% as inactive metabolites, <5% unchanged); fecal (approximately 30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid